

**RESEARCH****BOB ECONOMICS RESEARCH | MONTHLY ECONOMIC BUFFET**

Economic Round-up: April 2025

**COFORGE | TARGET: Rs 6,202 | -17% | SELL**

Robust growth likely in FY26. But pricey at 37x

**MAHINDRA & MAHINDRA | TARGET: Rs 3,689 | +22% | BUY**

Healthy performance all around; maintain BUY

**SUMMARY****INDIA ECONOMICS: MONTHLY ECONOMIC BUFFET**

Global growth and inflation outlook continues to be impacted by rapidly changing US tariff policies. This month, the US government signalled a softer stance on tariffs. The Liberation Day tariffs were paused for 90-days, even though the additional 10% tariff was still applicable. Reprieve was also provided to US auto manufacturers. US officials also hinted at substantial progress in trade talks with major trading partners. Further, while there were signs of an escalation in US-China trade war for the most part of the month, both the countries have expressed willingness to start trade negotiations. This is a welcome sign as the impact of tariff driven uncertainty can already be seen in early macro data points.

[Click here](#) for the full report.**COFORGE**

- 4QFY25 CC growth a tad below estimate but EBIT margin surprise +ve. FY25 organic rev. growth is likely in mid teen. FY26 hinted to be better.
- Order inflow bolstered by the Sabre mega deal (US\$1.56bn). Says risks associated with the deal covered. Ex-Sabre TCV down 4%.
- Raise FY26/FY27 USD revenue and EPS estimates a bit. While it will be among the growth leaders believe that is in the price at 37x FY26EPS.

[Click here](#) for the full report.

## MAHINDRA & MAHINDRA

- Automotive and tractor segment volume grew in double digits by ~16%/19% YoY; blended realisations gains ~7%/11% YoY/QoQ
- Auto EBIT margin up to 9.2% vs 8.8% YoY. FES market share at 41.2% (up 180 bps YoY), margins at 19.4% up from 16% YoY
- Maintain our earnings estimate and BUY rating, continue to value MM's core business at 24x 1YF P/E with unchanged TP of Rs 3,689

[Click here](#) for the full report.

## MONTHLY ECONOMIC BUFFET

05 May 2025

### Economic Round-up: April 2025

**Aditi Gupta**  
Economist

Global growth and inflation outlook continues to be impacted by rapidly changing US tariff policies. This month, the US government signalled a softer stance on tariffs. The Liberation Day tariffs were paused for 90-days, even though the additional 10% tariff was still applicable. Reprieve was also provided to US auto manufacturers. US officials also hinted at substantial progress in trade talks with major trading partners. Further, while there were signs of an escalation in US-China trade war for the most part of the month, both the countries have expressed willingness to start trade negotiations. This is a welcome sign as the impact of tariff driven uncertainty can already be seen in early macro data points.

Global central banks are also adopting a cautious approach awaiting more clarity on US tariffs and its impact on growth and inflation. In India, economic activity continues to recover at a steady pace. India remains well-insulated from tariff related shocks as the economy is largely domestic driven. There are indications that a trade deal with the US is likely before the end of the year. RBI reduced policy rates by 25bps in Apr'25 while also revising its growth and inflation projections downwards. Stance was also changed to accommodative signalling status quo or lower policy rates. Ample liquidity support has also been provided to improve transmission. We believe that the RBI is likely to reduce policy rate by another 50bps.

**Global growth prospects:** Global growth is expected to moderate to 2.8% in 2025 and 3% in 2026 as per the IMF's World Economic Outlook Report released in Apr'25. This is lower compared with an estimated 3.3% growth in 2024, and even lower than IMF's earlier estimates in Jan'25. Tariffs and policy uncertainty are likely to act as major drag on global economic activity. Growth in Advanced Economies (AEs) is expected at 1.4% in 2025 and 1.5% in 2026, marking a downward revision of 50bps and 30bps respectively from Jan'25. In the US, GDP growth is expected at 1.8% in 2025, with a sharp downward revision of 90bps. EMDEs are also expected to register lower growth of 3.7% versus 4.2% estimated earlier, led by sharp downward revisions in growth forecasts for China and Mexico. Global inflation is expected to moderate gradually to 4.2% in 2025 and 3.6% in 2026. Growth in world trade volumes is expected to fall to 1.7% in 2025 from 3.8% in 2026, due to the tariff uncertainty.

**Key macro data releases:** By a unanimous vote, **RBI's monetary policy committee** decided to reduce policy rates further by 25bps to 6%, marking the second consecutive rate cut. Stance was also changed to accommodative signalling either a pause or more rate cuts. Both growth and inflation projections for FY26 were revised lower to 6.5% and 4% respectively.



**SELL**

TP: Rs 6,202 | ▼ 17%

**COFORGE**

| IT Services

| 06 May 2025

## Robust growth likely in FY26. But pricey at 37x

- 4QFY25 CC growth a tad below estimate but EBIT margin surprise +ve. FY25 organic rev. growth is likely in mid teen. FY26 hinted to be better.
- Order inflow bolstered by the Sabre mega deal (US\$1.56bn). Says risks associated with the deal covered. Ex-Sabre TCV down 4%.
- Raise FY26/FY27 USD revenue and EPS estimates a bit. While it will be among the growth leaders believe that is in the price at 37x FY26EPS.

**Execution and proactive solutions the secret sauce:** It noted that its 8-year track record of good revenue performance has been largely due to execution excellence, being close to the customer and delivering proactive solutions. It indicated that in current times of macro driven slowdown, it depends on wallet share gains rather than an increase in budgets to drive growth.

**4QFY25 was strong:** Unlike for many of its peers, revenue grew 3.4% QoQ in CC terms. This is against our estimate of 4% growth. EBIT margin stood at 13.2%, 140bps higher than our estimate of 11.8%. A large portion of this has come from a better gross margin than we expected. Some of it has come from lower-than-expected SGA and ESOP costs.

**Order inflow bolstered by the Sabre deal:** The highlight of the year was the extremely strong order inflow which was bolstered by the 13-year US\$1.56bn Sabre (travel tech player) deal. Its full year TCV was US\$3.5bn (up 75%) with US\$2.1bn booked in 4Q alone. Without the Sabre deal the order inflow would have been down 4% for FY25. The 12-month executable order book at US\$1.5bn was also up 47% - part of it contributed by the Cigniti acquisition.

**Regarding Sabre risk (as it has weak financial position):** Coforge indicated that it is working closely with the company. It also stated that Sabre delevered to some extent recently through the sale of one of its units. It also stated that Coforge has taken credit insurance on the deal. Our concern in the current situation is not so much on the receivables part, but loss of revenue and profits and possible downgrade to consensus estimates and PE derating because of that.

**GCC seems to be an outsized element:** It was indicated that GCC business constituted 10% of the revenue of the Coforge. While all Indian companies recently have been touting their GCC credentials no one has put out a number on exposure. What we are concerned about on the GCC side is the potential for revenue discontinuity when there is insourcing at some point in time in the future. We are also concerned that some of this is possibly staff augmentation type of work.

**Girish Pai**

research@bobcaps.in

## Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	COFORGE IN/Rs 7,497
Market cap	US\$ 6.0bn
Free float	99%
3M ADV	US\$ 62.9mn
52wk high/low	Rs 10,027/Rs 4,287
Promoter/FPI/DII	0%/40%/50%


Source: NSE | Price as of 5 May 2025

## Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	121,912	152,747	180,796
EBITDA (Rs mn)	18,332	26,499	31,874
Adj. net profit (Rs mn)	8,107	14,219	17,547
Adj. EPS (Rs)	122.3	205.2	253.2
Consensus EPS (Rs)	141.7	211.1	258.6
Adj. ROAE (%)	16.2	21.4	24.2
Adj. P/E (x)	61.3	36.5	29.6
EV/EBITDA (x)	27.3	18.9	15.5
Adj. EPS growth (%)	(6.9)	67.8	23.4

Source: Company, Bloomberg, BOBCAPS Research

## Stock performance



Source: NSE



**BUY**

TP: Rs 3,689 | ▲ 22%

**MAHINDRA & MAHINDRA** | Automobiles

06 May 2025

## Healthy performance all around; maintain BUY

- Automotive and tractor segment volume grew in double digits by ~16%/19% YoY; blended realisations gains ~7%/11% YoY/QoQ
- Auto EBIT margin up to 9.2% vs 8.8% YoY. FES market share at 41.2% (up 180 bps YoY), margins at 19.4% up from 16% YoY
- Maintain our earnings estimate and BUY rating, continue to value MM's core business at 24x 1YF P/E with unchanged TP of Rs 3,689

**Milind Raginwar**

research@bobcaps.in

**Volume aids double-digit top-line growth:** In Q4 FY25, MM reported strong (SA) revenue growth of ~25%/3% YoY/QoQ, Rs 313.5 bn. This was driven by a blended volume growth of ~17% YoY to 341k vehicles, (7% QoQ decline). Net blended realisation per vehicle (NRPV) rose impressively by ~7% YoY and 11% QoQ to Rs 919.3k per vehicle, reflecting favourable product mix and pricing power.

**Automotive segment continues healthy delivery:** MM's Automotive business dominates revenue with 78.9% contribution in Q4FY25 (78.2% in Q4FY24). EBIT margin improved to 9.2% vs 8.8% YoY. The healthy contribution of the ICE segment, strong response to new launches like Thar Roxx, the 2 new EV launches and the LMM segment all contributed to the gains. The EV impact was ~1% on margins (overall EBITM excluding EV was ~10%).

**FES gaining pace:** At 41%, the tractor segment market share was up 180 bps YoY as volumes grew strongly by 20% YoY to 88k units. FES revenue share was stable at 20% YoY, with tractor margins at 19.4% up from 16% YoY. MM solidified leadership in tractors, with market share of 43.3% (+170 bps YoY) in FY25.

**Product pipeline remains strong:** For CY26, MM has outlined product launch to strengthen its position in the SUV, BEV, and LCV segments. Plans to introduce three SUVs, (two mid-cycle enhancements and one new model), with two BEVs and two LCVs (one ICE and one EV). The revised pipeline includes: 7 ICE SUVs, (5 new launches and 2 mid-cycle enhancements), 5 BEVs, reflecting a focused approach to EVs. MM plans 5 LCVs, (3 ICE models and 2 EVs), to cater to the CV demand.

**Overall healthy performance continues; maintain BUY:** We retain our earnings estimates for FY26e/FY27e, factoring in the healthy outlook from Automotive and FES segments, following healthy monsoons and a strong launch pipeline. We pencil in a 3Y EBITDA/PAT CAGR of 20%/17%. We value MM's core business at 24x 1-year P/E, a 10% premium to its long-term average (22x) resulting in an unchanged SOTP-based TP of Rs 3,689. This includes the value of subsidiaries of Rs347. We maintain our BUY rating (upside of 22%) and upward bias to our earnings estimates.

## Key changes

Target	Rating
◀ ▶	◀ ▶

Ticker/Price	MM IN/Rs 3,022
Market cap	US\$ 44.9bn
Free float	81%
3M ADV	US\$ 115.4mn
52wk high/low	Rs 3,271/Rs 2,160
Promoter/FPI/DII	19%/37%/29%


Source: NSE | Price as of 5 May 2025

## Key financials

Y/E 31 Mar	FY25P	FY26E	FY27E
Total revenue (Rs mn)	11,64,837	13,06,400	14,91,038
EBITDA (Rs mn)	1,62,747	1,93,888	2,22,525
Adj. net profit (Rs mn)	1,18,550	1,52,573	1,70,307
Adj. EPS (Rs)	98.9	127.3	142.1
Consensus EPS (Rs)	98.9	116.8	131.3
Adj. ROAE (%)	20.8	22.5	20.9
Adj. P/E (x)	30.5	23.7	21.3
EV/EBITDA (x)	22.8	18.9	16.7
Adj. EPS growth (%)	10.6	28.7	11.6

Source: Company, Bloomberg, BOBCAPS Research | P – Provisional

## Stock performance



Source: NSE



**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.**

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.



BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "**Losses**") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "**MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.